Deflazacort (English Wikipedia)

Analysis of information sources in references of the Wikipedia article "Deflazacort" in English language version.

refsWebsite

Global rank English rank

6nih.gov

4^th place

4fda.gov

447^th place

338^th place

3doi.org

2^nd place

2wsj.com

79^th place

65^th place

1books.google.com

3^rd place

1julpharbd.com

low place

1semanticscholar.org

11^th place

8^th place

1archive.today

14^th place

1medicines.org.uk

3,823^rd place

2,387^th place

1chicagotribune.com

95^th place

70^th place

1web.archive.org

1^st place

1fortune.com

433^rd place

284^th place

1ptcbio.com

low place

1bulas.med.br

low place

archive.today

"Calcort". electronic Medicines Compendium. June 11, 2008. Archived from the original on December 24, 2012. Retrieved on October 28, 2008.

books.google.com

Fischer J, Ganellin CR (2006). Analogue-based Drug Discovery. John Wiley & Sons. p. 486. ISBN 9783527607495.

bulas.med.br

"Substâncias: DEFLAZACORT" (in Portuguese). Centralx. 2008. Retrieved on October 28, 2008.

chicagotribune.com

Hirst EJ (January 19, 2015), Duchenne muscular dystrophy drug could get OK for U.S. sales in 2016, The Chicago Tribune, retrieved February 13, 2017, has been shown to prolong lives ... a progressive and fatal disease that has no drug treatment available in the US

doi.org

Nayak S, Acharjya B (December 19, 2008). "Deflazacort versus other glucocorticoids: a comparison". Indian Journal of Dermatology. 53 (4): 167–170. doi:10.4103/0019-5154.44786. PMC 2763756. PMID 19882026.
Möllmann H, Hochhaus G, Rohatagi S, Barth J, Derendorf H (July 1995). "Pharmacokinetic/pharmacodynamic evaluation of deflazacort in comparison to methylprednisolone and prednisolone". Pharmaceutical Research. 12 (7): 1096–100. doi:10.1023/a:1016287104656. PMID 7494809. S2CID 9920545.
Parente L (January 2017). "Deflazacort: therapeutic index, relative potency and equivalent doses versus other corticosteroids". BMC Pharmacology & Toxicology. 18 (1): 1. doi:10.1186/s40360-016-0111-8. PMC 5216559. PMID 28057083.

fda.gov

New Drug Therapy Approvals 2017 (PDF). U.S. Food and Drug Administration (FDA) (Report). January 2018. Retrieved 16 September 2020.
"FDA approves drug to treat Duchenne muscular dystrophy". U.S. Food and Drug Administration (Press release). Retrieved 18 February 2017. This article incorporates text from this source, which is in the public domain.
"FDA approves drug to treat Duchenne muscular dystrophy". www.fda.gov. 2017-02-09. Retrieved 2017-02-10.

accessdata.fda.gov

"Drugs@FDA: FDA Approved Drug Products". U.S. Food and Drug Administration (FDA).

fortune.com

Mukherjee CS (February 10, 2017). "Brainstorm Health Daily". Retrieved February 13, 2017.

julpharbd.com

"Refla: deflazacort" (PDF).

medicines.org.uk

emc.medicines.org.uk

"Calcort". electronic Medicines Compendium. June 11, 2008. Archived from the original on December 24, 2012. Retrieved on October 28, 2008.

nih.gov

pubmed.ncbi.nlm.nih.gov

Nayak S, Acharjya B (December 19, 2008). "Deflazacort versus other glucocorticoids: a comparison". Indian Journal of Dermatology. 53 (4): 167–170. doi:10.4103/0019-5154.44786. PMC 2763756. PMID 19882026.
Möllmann H, Hochhaus G, Rohatagi S, Barth J, Derendorf H (July 1995). "Pharmacokinetic/pharmacodynamic evaluation of deflazacort in comparison to methylprednisolone and prednisolone". Pharmaceutical Research. 12 (7): 1096–100. doi:10.1023/a:1016287104656. PMID 7494809. S2CID 9920545.
Parente L (January 2017). "Deflazacort: therapeutic index, relative potency and equivalent doses versus other corticosteroids". BMC Pharmacology & Toxicology. 18 (1): 1. doi:10.1186/s40360-016-0111-8. PMC 5216559. PMID 28057083.

ncbi.nlm.nih.gov

Nayak S, Acharjya B (December 19, 2008). "Deflazacort versus other glucocorticoids: a comparison". Indian Journal of Dermatology. 53 (4): 167–170. doi:10.4103/0019-5154.44786. PMC 2763756. PMID 19882026.
Parente L (January 2017). "Deflazacort: therapeutic index, relative potency and equivalent doses versus other corticosteroids". BMC Pharmacology & Toxicology. 18 (1): 1. doi:10.1186/s40360-016-0111-8. PMC 5216559. PMID 28057083.

dailymed.nlm.nih.gov

"Emflaza- deflazacort tablet Emflaza- deflazacort suspension". DailyMed. 29 January 2020. Retrieved 17 September 2020.

ptcbio.com

ir.ptcbio.com

"PTC Therapeutics Completes Acquisition of Emflaza for the Treatment of Duchenne Muscular Dystrophy in the U.S." PTC Therapeutics, Inc.

semanticscholar.org

api.semanticscholar.org

Möllmann H, Hochhaus G, Rohatagi S, Barth J, Derendorf H (July 1995). "Pharmacokinetic/pharmacodynamic evaluation of deflazacort in comparison to methylprednisolone and prednisolone". Pharmaceutical Research. 12 (7): 1096–100. doi:10.1023/a:1016287104656. PMID 7494809. S2CID 9920545.

web.archive.org

"Marathon Pharmaceuticals to Charge $89,000 for Muscular Dystrophy Drug". www.wsj.com. 2017-02-10. Archived from the original on 2017-02-10. Retrieved 2017-02-10.

wsj.com

"Marathon Pharmaceuticals to Charge $89,000 for Muscular Dystrophy Drug". www.wsj.com. 2017-02-10. Archived from the original on 2017-02-10. Retrieved 2017-02-10.
Walker J, Pulliam S (February 13, 2017), Marathon Pharmaceuticals to Charge $89,000 for Muscular Dystrophy Drug After 70-Fold Increase, The Wall Street Journal, retrieved February 13, 2017, FDA-approved deflazacort treats rare type of disease affecting boys